U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07496008) titled 'Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population' on March 22.
Brief Summary: Esconazole, as a novel triazole antifungal drug, has broad-spectrum antifungal activity, good tissue penetration and low toxicity risk. It has been recommended by domestic and international guidelines as a first-line treatment for invasive fungal infections. Due to its good pharmacokinetic properties and the lack of evidence to associate plasma concentration with efficacy and toxicity, therapeutic drug monitoring is not routinely recommended at present. However, the pharmacokinetic characteristics of i...